Patent · US Active

RNAi inhibition of alpha-ENaC expression

US11208662B2 · kind B2 · utility

0Cited by

25References

21Claims

0Family size

Assignee

Arrowhead Pharmaceuticals, Inc. · US

Inventors

Gino Van Heeke · Gainesville, US
Emma Hickman · Horsham, GB
Henry Luke Danahay · Horsham, GB
Pamela Tan · Kulmbach, DE
Anke Geick · Bayreuth, DE
Hans-Peter Vornlocher · Bayreuth, DE

Key dates

Filing date	Jan 24, 2020
Grant date	Dec 28, 2021
Priority date	—
Expiry date	Jan 24, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.